February 17, 2009 – The National Institutes of Health have given UCSD’s Rebecca and John Moores Cancer Center a $7.5 million grant to develop new methods for detecting cancer and monitoring its treatment at the newly established In Vivo Cellular and Molecular Imaging Center.
“We want to develop diagnostic tools that define the cancer at its earliest stage, not just whether it is there, but its characteristics,” said Robert Mattrey, M.D., co-principal investigator of the project and radiology professor at the UCSD School of Medicine.
Along with pharmacology, chemistry and biochemistry professor — and recent Nobel laureate — Roger Tsien, Mattrey will lead a project to improve strategies for detecting enzymes called matrix metalloproteinases, which aggressively break down tissue and enable cancers to spread. The research team is developing imaging tools for conducting ultrasounds that will help detect enzymes in prostate and breast cancers.
Mattrey said that clearly determining the aggressiveness of a cancer will likely influence the treatment decisions of both doctors and patients.
In another project, co-principal investigator and professor of radiology David Vera, Ph.D., will collaborate with medicine professor Stephen Howell, M.D., to use nuclear imaging and ultrasounds in virtually tracking cancer cells and monitoring the effectiveness of an experimental, platinum-based chemotherapy drug.
“It’s difficult to know if a drug is reaching its molecular target,” Mattrey said. “It’s not just a matter of knowing that the drug reaches the tumor, but also if it was able to inhibit or stop the chemical reaction that it was designed to do.”
A portion of the grant will also fund a study led by assistant professor of pathology Dwayne Stupack, Ph.D., involving the use of nanoparticles to detect changes in the blood vessels associated with tumors. Stupack hopes to develop an imaging system that will expose tumors in their earliest stages.

Source: The Guardian, University of California, San Diego

For more information: www.ucsdguardian.org


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Subscribe Now